Norden Andrew D, Drappatz Jan, Ciampa Abigail Slate, Doherty Lisa, LaFrankie Debra Conrad, Kesari Santosh, Wen Patrick Y
Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Neuro Oncol. 2009 Feb;11(1):92-5. doi: 10.1215/15228517-2008-071. Epub 2008 Aug 29.
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints.
抗血管生成药物已成为复发性恶性胶质瘤（MG）患者的有效治疗选择。尽管这类药物通常耐受性良好，但仍有罕见的危及生命的并发症被报道，包括血栓栓塞、出血和胃肠道（GI）穿孔。我们描述了244例胶质瘤患者在接受抗血管生成药物联合化疗和皮质类固醇治疗期间发生的6例胃肠道穿孔病例（2.5%）。两名患者死于该并发症，其他患者康复。由于胃肠道穿孔是一种危及生命但可治疗的并发症，神经肿瘤学家在抗血管生成药物治疗的患者出现腹痛和其他胃肠道不适时，应保持较低的阈值来考虑这一并发症。
